What is the benefit-risk ratio of bisphosphonate therapy for individuals over 75 without manifest osteoporosis, but with corticosteroid or other treatment that can induce bone loss?
Abstract
Bisphosphonates may offer fracture risk reduction in individuals over 75 on treatments like corticosteroids, but potential risks, such as atypical femur fractures and osteonecrosis, necessitate careful benefit-risk assessment.
Fields of Study & Subjects
Bone health and osteoporosis research
Bone health and treatments
Menopause: Health Impacts and Treatments
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 16 February 2026
- Language
- EN